Samuel Carter, MD
Internal Medicine · Joplin, MONPI 1760428973
Payments from drug & device makers
Across 810 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Amgen$906
- Abbott$870
- Lilly USA, LLC$861
- Boehringer Ingelheim$820
- plus $6K from 29 others
What the payments were for
- Food & beverage$11,27990%
- Education$370%
- Gifts$5264%
- Other$6435%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 89 | $1,544 |
| Novo Nordisk | 96 | $1,226 |
| Amgen | 67 | $906 |
| Abbott | 49 | $870 |
| Lilly USA, LLC | 65 | $861 |
| Boehringer Ingelheim | 53 | $820 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $776 |
| Pfizer | 59 | $659 |
| Baxter Healthcare | 1 | $643 |
| Welch Allyn | 1 | $526 |
| Kowa Pharmaceuticals America, Inc. | 59 | $494 |
| Merck | 31 | $463 |
| Dexcom, Inc. | 23 | $376 |
| GSK | 24 | $335 |
| AbbVie(2 entities) | 17 | $257 |
| Idorsia Pharmaceuticals US Inc | 15 | $221 |
| Sanofi-aventis U.S. LLC | 18 | $208 |
| Johnson & Johnson | 9 | $143 |
| Currax Pharmaceuticals LLC | 10 | $143 |
| Exact Sciences | 9 | $143 |
| Bayer | 8 | $132 |
| Biohaven Pharmaceuticals, Inc. | 10 | $113 |
| Novartis | 7 | $95 |
| Teva Pharmaceuticals USA, Inc. | 7 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $81 |
| Astellas Pharma US Inc | 4 | $69 |
| Medtronic(2 entities) | 4 | $53 |
| Amarin Pharma, Inc. | 4 | $50 |
| Sumitomo Pharma America, Inc. | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Insulet Corporation | 1 | $32 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Seqirus USA Inc | 1 | $27 |
| Eisai Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,485 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 234 | $208,946 |
| OzempicSemaglutide | 146 | $187,955 |
| EliquisApixaban | 196 | $146,555 |
| MounjaroTirzepatide | 105 | $120,056 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $91,567 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 249 | $77,910 |
| XareltoRivaroxaban | 55 | $57,648 |
| FarxigaDapagliflozin Propanediol | 59 | $42,884 |
| TrulicityDulaglutide | 39 | $42,574 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $28,821 |
| JanuviaSitagliptin Phosphate | 21 | $22,296 |
| Repatha SureclickEvolocumab | 15 | $21,313 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $18,466 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $16,291 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $13,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat | $820 | $230,067263 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix | $335 | $199,299460 claims |
| Novo NordiskOzempic | $1,226 | $187,955146 claims |
| Lilly USA, LLCMounjaro, Trulicity | $861 | $162,629144 claims |
| PfizerEliquis | $659 | $146,555196 claims |
| Johnson & JohnsonXarelto | $143 | $57,64855 claims |
| AstraZenecaFarxiga | $1,544 | $42,88459 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $208 | $28,82116 claims |
| MerckJanuvia | $463 | $22,29621 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $776 | $19,20563 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $42 | $10,53816 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $494 | $9,98015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Joplin
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.